NCT02440789View on ClinicalTrials.gov

Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 21, 2015

Primary Completion Date

November 2, 2017

Study Completion Date

February 1, 2018

Conditions
HIV-1 Infection
Interventions
DRUG

Sirolimus

"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."

Trial Locations (10)

10011

Weill Cornell Uptown CRS (7803), New York

14642

31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester

20005

Whitman Walker Health CRS (31791), Washington D.C.

30308

The Ponce de Leon Center CRS (5802), Atlanta

33136

Univ. of Miami AIDS CRS (901), Miami

45267

Univ. of Cincinnati CRS (2401), Cincinnati

63110

Washington University CRS (2101), St Louis

77030

Houston AIDS Research Team CRS (31473), Houston

94110

801 University of California, San Francisco HIV/AIDS CRS, San Francisco

98104

University of Washington AIDS CRS (1401), Seattle

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT02440789 - Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) | Biotech Hunter | Biotech Hunter